ROIV
$35.72+0.62%
as of close, Oct 2, 2026
☾ AH $35.72 +0.62%
Roivant Sciences Ltd.Stock · Health CareNasdaq Composite 0.05%Russell 1000 0.02%US Stock Market 0.02%Russell 3000 0.02%
ROIV — Roivant Sciences Ltd. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeEEEE
5.010.015.020.025.030.035.040.0050.0M$35.72—20202022202320252026
2026-10-02
Price$35.72
MA20$36.42
MA50$32.44
Vol12.9M
Key stats
Price data
- Price
- $35.72
- Change YTD
- +64.61%
- Next earnings
- Nov 9, 2026
- Market cap
- 25.8B
- Enterprise value
- 22.8B
- Shares outstanding
- 722.3M
- 52W low
- $15.25
- 52W high
- $42.50
- From 52W high
- -15.95%
- From 52W low
- +134.23%
- 52W range
- 75%
- Beta
- 1.12
Volume
- Rel volume
- 0.49×
- 30D volume
- 9M
- 30D $ vol
- 339.4M
Insider trading
- Insider net 1W
- −$7.3M
- Insider net 1M
- −$8.5M
- Insider net 3M
- −$59.2M
- Insider net 1Y
- −$484.3M
Form 4 transactions by trade date, as filed; latest on file 2026-09-30.
Fundamentals
- Sales (ttm)
- 7.5M
- Sales/share
- $0.01
- EPS (ttm)
- -$0.38
- FCF (ttm)
- -821.1M
- FCF/share
- -$1.14
- Book value/share
- $5.86
- Net margin
- -3534.96%
- ROE
- -6.29%
- ROA
- -5.02%
- Current ratio
- 16.72
Growth (CAGR, ttm) · 10Y
- Sales
- -67.61%-46.36%-19.68%n/a
- Shares
- +5.78%-2.18%+26.54%n/a
Per-share growth (CAGR, ttm) · 10Y
- Sales/share
- -69.38%-45.17%-21.24%n/a
- Book value/share
- -7.95%+70.56%-5.42%n/a
- Price
- +123.65%+50.31%+30.73%n/a
- Total return
- +123.65%+50.31%+30.73%n/a
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- -94.4×
- Fwd P/E
- -21.5×
- P/S (ttm)
- 3425.6×
- P/B (mrq)
- 6.1×
- EV/Sales (ttm)
- 3027.0×
- FCF yield (ttm)
- -3.18%
- Buyback yield (realized, 1y)
- -5.78%
- Shareholder yield (realized, 1y)
- -5.78%
- Buyback yield (cash, ttm)
- -0.01%
- Shareholder yield (cash, ttm)
- -0.01%
Vs own 10Y history
- P/S
- 97th
- P/B
- 83rd
Bar = where today’s multiple sits in ROIV’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-02
1D
+0.62%
5D
-0.22%
1M
+4.51%
3M
+1.68%
YTD
+64.61%
1Y
+123.53%
5Y
+282.03%
Recent filings
- Sep 30Insider sale · Venker Eric (President & Immunovant CEO) sold 200,000 shares for $7.3M at $36.62 under a 10b5-1 plan
- Sep 188-K · Shareholder vote results
- Sep 15Insider sale · Fitzgerald Meghan (Director) sold 5,112 shares for $203K at $39.68–$40.45 under a 10b5-1 plan
- Sep 15Insider sale · Epperly Melissa B, (Director) sold 4,938 shares for $196K at $39.65–$40.38 under a 10b5-1 plan
- Sep 8Insider sale · Fitzgerald Meghan (Director) sold 20,000 shares for $798K at $39.90 under a 10b5-1 plan
Financial statements
Open full ROIV financials →Loading financial statements…
Related Health Care
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| NVS | Novartis AG | -13.21% | -0.04% |
| NVO | Novo Nordisk A/S | -20.21% | -0.21% |
| SNY | Sanofi ADS | -10.23% | -1.84% |
| GSK | GSK plc American Depositary Shares (Each representing two Ordinary Shares) | -6.76% | -0.32% |
| NTRA | Natera Inc. | +26.20% | +0.46% |
| ARGX | argenx SE American Depositary Shares | -12.90% | -1.79% |
| TAK | Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) | -3.09% | +0.00% |
| TEVA | Teva Pharmaceutical Industries Limited American Depositary Shares | +5.44% | +0.56% |
